Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2013
Marseillevirus prevalence in multitransfused patients suggests blood transmission.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Popgeorgiev Nikolay, Colson Philippe, Thuret Isabelle, Chiarioni Jacques, Gallian Pierre, Raoult Didier, Desnues Christelle
Аннотация
BACKGROUND: Emerging viral infections in humans are appearing at an increasing rate. Recently, we identified a new Marseillevirus, named Giant Blood Marseillevirus (GBM), by performing viral metagenomics on asymptomatic blood donors.
OBJECTIVES: To study and compare the prevalence of Marseillevirus between asymptomatic blood donors and thalassemia patients.
DESIGN: Here, we present a combined molecular and serological study on 174 asymptomatic blood donors and 22 patients with thalassemia who receive repeated blood transfusions to estimate the prevalence of Marseillevirus in these two populations.
RESULTS: We identified Marseillevirus genomic DNA in 4% of donors, whereas 9.1% of the thalassemia patients were positive for this virus. Moreover, IgG seropositivity was detected in 22.7% of patients in the thalassemia group, whereas this seropositivity was observed in 12.6% of the blood donor population.
CONCLUSION: These results suggest that Marseillevirus infection is not rare in healthy persons and may be transmitted by transfusion, thus raising speculation regarding the long-term consequences of this viral infection, particularly in patients requiring repeated blood transfusions.
OBJECTIVES: To study and compare the prevalence of Marseillevirus between asymptomatic blood donors and thalassemia patients.
DESIGN: Here, we present a combined molecular and serological study on 174 asymptomatic blood donors and 22 patients with thalassemia who receive repeated blood transfusions to estimate the prevalence of Marseillevirus in these two populations.
RESULTS: We identified Marseillevirus genomic DNA in 4% of donors, whereas 9.1% of the thalassemia patients were positive for this virus. Moreover, IgG seropositivity was detected in 22.7% of patients in the thalassemia group, whereas this seropositivity was observed in 12.6% of the blood donor population.
CONCLUSION: These results suggest that Marseillevirus infection is not rare in healthy persons and may be transmitted by transfusion, thus raising speculation regarding the long-term consequences of this viral infection, particularly in patients requiring repeated blood transfusions.